Highest-materiality recent filing
Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.
Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook
Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.
Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.
Champions Oncology reports record annual revenue $57M (+14%), net income $4.6M for FY2025
Record annual revenue $57M, up 14% YoY; net income $4.6M vs loss of $7.4M prior year.
Champions Oncology appoints Robert Brainin as CEO effective Aug 25, 2025
Robert Brainin named CEO, effective August 25, 2025; he was a Board member since Feb 2021.
Revenue up 42% YoY to $17.0M; net income of $4.5M vs loss of $2.6M in prior year quarter.
Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M
Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%
Champions Oncology President Brady Davis passes away unexpectedly
President Brady Davis passed away unexpectedly in the week ending October 3, 2024.
Champions Oncology Q1 revenue $14.1M, net income $1.3M, adjusted EBITDA $2.0M
Revenue rose 12% YoY to $14.1M; net income of $1.3M vs. loss of $2.6M a year ago.
Champions Oncology reports FY2024 revenue down 7% to $50.2M; Q4 adjusted EBITDA turns positive $884K
Q4 revenue $14.0M (+7% YoY); Q4 adjusted EBITDA income $884K vs loss $922K prior year.
Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M
Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.
Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat
Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.
Champions Oncology Q1 revenue $12.6M, down 9%; operating loss widens to $2.6M
Revenue $12.6M vs $13.7M YoY (-8.6%); gross margin 38.8% vs 48.7%.
Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.
Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M
Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.
Champions Oncology reports record Q2 revenue of $14.3M, cuts FY growth outlook to 10-15%
Record quarterly revenue of $14.3M, up 21% YoY from $11.8M.
Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K
Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.
Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023
Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.
Champions Oncology Q3 revenue record $13.2M, up 22% YoY; adj. EBITDA $1.5M
Revenue of $13.2M for quarter ended Jan 31, 2022, a 22% increase from $10.8M in prior year.
Champions Oncology reports record Q2 revenue $11.8M, up 17% YoY; operating income $263K
Record quarterly revenue of $11.8M, up 17% from $10.1M year ago.
Champions Oncology Q1 revenue record $11.3M, up 18% YoY; non-GAAP op income $422k
Record quarterly revenue of $11.3M, +17.9% YoY, driven by larger studies and platform expansion.
FY2021 revenue $41.0M, up 28% from $32.1M; Q4 revenue $10.6M, up 21% from $8.8M.
Champions Oncology, Inc. deeply regrets to announce that its President, Mr. Brady Davis, passed away unexpectedly this week.
On October 17, 2023, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Brady Davis to serve as the Company’s President, effective as of October 9, 2023.
Max materiality 0.85 · Median 0.70 · Most common event earnings